Chinese Journal of Tissue Engineering Research ›› 2013, Vol. 17 ›› Issue (8): 1473-1480.doi: 10.3969/j.issn.2095-4344.2013.08.024
Previous Articles Next Articles
Wang Dan1, Jiang Hang-hang2
Received:
2012-10-18
Revised:
2012-12-27
Online:
2013-02-19
Published:
2013-02-19
Contact:
Jiang Hang-hang, Studying for master’s degree, China Medical University, Shenyang 110000, Liaoning Province, China
Jwb20082000@yahoo.cn
About author:
Wan Dan, Associate chief pharmacist, Seventh People’s Hospital of Shenyang, Shenyang 110003, Liaoning Province, China
qywd123@yahoo.cn
CLC Number:
Wang Dan, Jiang Hang-hang. Characteristics and experimental application of polylactic acid copolymer composite sustained-release drug materials[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(8): 1473-1480.
肿瘤是一种常见病与多发病,严重威胁着人类的健康,其死亡率仅次于心脑血管疾病的死亡率,并且正在逐年增加。恶性肿瘤的治疗主要以化疗为主,各种化疗药物如5-氟尿嘧啶、阿霉素、表阿霉素、环磷酰胺、长春新碱、喜树碱和紫杉醇等在恶性肿瘤的治疗中发挥重要的作用,但是绝大部分药物具有较强的毒性以及非靶向性,而微粒系统在肿瘤细胞表面的吸附能力较强,能够增强肿瘤细胞的摄粒活性,从而提高药物的靶向性,明显降低药物的毒副作用,增强治疗效果。诸多研究对5-氟尿嘧啶、阿霉素、表阿霉素以及紫杉醇的聚乳酸共聚物的缓释药物特征进行了分析。 2.1.2 聚乳酸抗菌、抗病毒药物缓释材料的特征 应用抗菌、抗病毒聚乳酸聚合物缓释材料可以降低药物的毒性,提高治疗效果,原因是细菌和病毒感染的主要部位肝、脾等器官也是药物缓释微粒的靶向器官,此外,微粒可以进入细胞内释放药物,并且可以持续较长时间的药物作用,从而消除细菌和病毒的耐药性。文章对盐酸左氧氟沙星、替硝唑以及阿奇霉素聚乳酸共聚物的缓释药物特征进行了研究分析,见表2。"
2.1.5 聚乳酸降胆固醇药物缓释材料的特征 洛伐他汀是降低胆固醇药物,半衰期较短,口服药物后血药浓度变化较大,加入聚乳酸载体后能够长时间维持药物的血药浓度,延长药物作用时间。张敏[29]对洛伐他汀聚乳酸微球的药物缓释性能进行了研究分析,实验结果发现洛伐他汀聚乳酸微球的形态圆整,粒径分布均匀,最佳微球粒径65.8 μm,载药量32.2%,包封率81.8%,可持续释放药物达10 d,累积释放药量34.8%。同时研究还发现载体材料的亲水性越高,微球的包封率和载药量越大,药物释放速率也越快。 2.2 聚乳酸共聚物复合药物缓释材料的动物实验应用 2.2.1 聚乳酸抗结核药物缓释材料治疗结核的应用实验 刘江涛等[24]和胡春晖[26]分别对异烟肼聚乳酸共聚物和利福平聚乳酸共聚物进行了药物缓释作用的动物实验研究,同样显示出聚乳酸抗结核药物良好的药物缓释特征,具体实验方法及结果见表5。"
[1] Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822. [2] Deitzel JM, Kleinmeyer JD, Hirvonen JK, et al. Controlled deposition of electrospun poly(ethylene oxide) fibers. Polymer. 2000;42:8163-8170.[3] Zussman E, Burman M, Yarin AL, et al. Tensile deformation of electrospun nylon-6,6 nanofibers. Journal of Polymer Science B: Polymer Physics. 2006;44:1482-1489.[4] Auras R, Harte B, Selke S. An overview of polylactides as packaging materials. Macromol Biosci. 2004;4(9):835-864. [5] 石淑先,夏宇正,郭祖鹏,等.聚D,L-乳酸的合成及表征[J].弹性体,2002,12(6):10-13. [6] Drumright RE, Gruber PR, Henton DE. Polylactic acid technology. Advanced Materials. 2000;12:1841-1846.[7] Pelouze J. Memoire sure l'acide lactique. Annual Chimie. 1845;3(13):257-268.[8] Carothers WH, Dorough GL, Van Natta FJ. Studies of polymerization and ring formation. X. The reversible polymerization of six-membered cyclic ester. Journal of the American Chemical Society. 1932;54:761-772. [9] Lowe CE. Preparation of high molecular weight polyhydroxyacetic ester. US Patent, 2668162,1954.[10] Yolles S, Leaffe T, Ward L, et al. Controlled release of biologically active drugs. Bull Parenter Drug Assoc. 1976; 30(6):306-312. [11] Uchida T, Yoshida K, Ninomiya A, et al. Optimization of preparative conditions for polylactide (PLA) microspheres containing ovalbumin. Chem Pharm Bull (Tokyo). 1995;43(9): 1569-1573. [12] Cao X, Schoichet MS. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials. 1999;20(4):329-339. [13] 郭圣荣.医药用生物降解性高分子材料[M].北京:化学工业出版社,2003.42-43.[14] 中国知网.中国学术期刊总库[DB/OL].2012-11-28. https://www.cnki.net [15] 冯芳.5-FU载药纳米微粒的制备、表征及体外实验[D].甘肃:兰州大学,2009:1-46.[16] 毕秀增,潘伟华,南开辉,等.5-氟尿嘧啶缓释剂制备及体外释药性能比较[J].中国组织工程研究,2012,16(8):1430-1434.[17] 周志敏.抗肿瘤药物表阿霉素缓释制剂及聚乳酸自组装行为的研究[D].福建:厦门大学,2006:1-82.[18] 蔡敏娴,陈志奎,林礼务,等.载多烯紫杉醇聚乳酸-羟基乙酸微球的制备、表征及其药物稳定性[J].中国组织工程研究与临床康复,2010,14(21):3856-3860.[19] 叶社房,侯振清,周志敏,等.植入型表阿霉素缓释药膜的制备及体内抑瘤活性[J].中国生物医学工程学报,2008,27(4): 586-590.[20] 刘杰,徐伟华,金成,等.载阿霉素PLGA纳米微球的制备及性质研究[J].现代生物医学进展,2010,10(24):4661-4663.[21] 胡庆军.聚DL-乳酸在HA复合材料与药物缓释中的应用[D].湖北:华中科技大学,2006:1-59.[22] 刘娟,肖丽英,李伟,等.可吸收聚乳酸-替硝唑抗菌缓释剂体外药物释放效果的测定[J].华西口腔医学杂志,2005,23(3):237-239.[23] 王哲,张秀梅,倪宏哲,等.聚乳酸载阿奇霉素微球包裹和体外释放行为[J].中国生物医学工程学报,2009,28(2):314-316.[24] 刘江涛,王永清,夏侃,等.异烟肼聚乳酸缓释体的制备及体内外释药特性[J].中国脊柱脊髓杂志,2008,18(4):290-293.[25] 叶向阳,孙湘,贾会文,等.利福平/聚乳酸-聚羟基乙酸缓释微球的制备及特性[J].中国组织工程研究与临床康复,2011,15(51): 9608-9612.[26] 胡春晖.利福平微球-原位凝胶复合缓释载体的研究[D].北京:北京协和医学院,2011:1-109.[27] 肖莉,张韵慧,崔颖,等.尼莫地平聚乳酸缓释微球的制备及其药剂学性质[J].中国医院药学杂志,2008,28(3):194-198.[28] 刘国磊,王帅,王静,等.长春西汀聚乳酸-聚乙醇酸缓释微球的研制[J].中国药房,2012,23(13):1203-1206.[29] 张敏.洛伐他汀聚乳酸微球的制备及释药特性[D].北京:北京化工大学,2011:1-89.[30] 胡婧.羟基喜树碱缓释片脑内植入治疗脑胶质瘤的研究[D].重庆:第三军医大学,2008:1-68.[31] 索新,刘伟,郭永川,等.可生物降解高分子超细纤维PLA药物缓释体作用于脑胶质瘤的体外研究[J].中国微侵袭神经外科杂志, 2006, 11(12):558-561.[32] Asmus LR, Tille JC, Kaufmann B, et al. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer. J Control Release. 2012;165(3):199-206. [33] Ranjan AP, Mukerjee A, Helson L, et al. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnology. 2012; 10:38. [34] Asmus LR, Kaufmann B, Melander L, et al. Single processing step toward injectable sustained-release formulations of Triptorelin based on a novel degradable semi-solid polymer. Eur J Pharm Biopharm. 2012;81(3):591-599. [35] Agrawal R, Shanavas A, Yadav S, et al. Polyelectrolyte coated polymeric nanoparticles for controlled release of docetaxel. J Biomed Nanotechnol. 2012;8(1):19-28. [36] Parker T, Davé V, Falotico R, et al. Control of cilostazol release kinetics and direction from a stent using a reservoir-based design. J Biomed Mater Res B Appl Biomater. 2012;100(3):603-610. [37] Asmus LR, Gurny R, Möller M. Solutions as solutions--synthesis and use of a liquid polyester excipient to dissolve lipophilic drugs and formulatesustained-release parenterals. Eur J Pharm Biopharm. 2011;79(3):584-591. [38] Zhan W, Zhang X. Preparation of sustained release microspheres containing extracts from Caulis sinomenii with polylactic acid and their release property in vitro. Zhongguo Zhong Yao Za Zhi. 2010;35(16):2142-2145. [39] Wang TW, Wu Y, Li MJ, et al. Preparation and drug release property of paclitaxel nanoparticles. Zhong Yao Cai. 2009; 32(9): 1447-1449. [40] Kang C, Yuan X, Zhong Y, et al. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. Technol Cancer Res Treat. 2009;8(1):61-70. [41] Gao H, Ping Q, Gu Y. Fabrication, characterization and drug release characteristics of drug loaded poly (L-lactic acid) fiber. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008;25(4): 870-873. [42] Rothen-Weinhold A, Besseghir K, Vuaridel E, et al. Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants. Eur J Pharm Biopharm. 1999;48(2):113-121. [43] Pardridge WM. Drug targeting to the brain. Pharm Res. 2007; 24(9):1733-1744. [44] Mariette B, Coudane J, Vert M. Interactions of GRF(1-29)NH2 with plasma proteins and their effects on the release of the peptide from a PLAGA matrix. J Control Release. 2005;106(3): 253-262. [45] Yamagata T, Morishita M, Kavimandan NJ, et al. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. J Control Release. 2006;112(3):343-349. [46] Edelman ER, Langer R. Optimization of release from magnetically controlled polymeric drug release devices. Biomaterials. 1993;14(8):621-626. |
[1] | Jiang Yong, Luo Yi, Ding Yongli, Zhou Yong, Min Li, Tang Fan, Zhang Wenli, Duan Hong, Tu Chongqi. Von Mises stress on the influence of pelvic stability by precise sacral resection and clinical validation [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(9): 1318-1323. |
[2] | Zhang Tongtong, Wang Zhonghua, Wen Jie, Song Yuxin, Liu Lin. Application of three-dimensional printing model in surgical resection and reconstruction of cervical tumor [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(9): 1335-1339. |
[3] | Zhang Chao, Lü Xin. Heterotopic ossification after acetabular fracture fixation: risk factors, prevention and treatment progress [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(9): 1434-1439. |
[4] | Gu Xia, Zhao Min, Wang Pingyi, Li Yimei, Li Wenhua. Relationship between hypoxia inducible factor 1 alpha and hypoxia signaling pathway [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(8): 1284-1289. |
[5] | Zhang Xiumei, Zhai Yunkai, Zhao Jie, Zhao Meng. Research hotspots of organoid models in recent 10 years: a search in domestic and foreign databases [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(8): 1249-1255. |
[6] | Zhao Min, Feng Liuxiang, Chen Yao, Gu Xia, Wang Pingyi, Li Yimei, Li Wenhua. Exosomes as a disease marker under hypoxic conditions [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(7): 1104-1108. |
[7] | Jiao Hui, Zhang Yining, Song Yuqing, Lin Yu, Wang Xiuli. Advances in research and application of breast cancer organoids [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(7): 1122-1128. |
[8] | Nie Huijuan, Huang Zhichun. The role of Hedgehog signaling pathway in transforming growth factor beta1-induced myofibroblast transdifferentiation [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(5): 754-760. |
[9] | Fu Shuanhu, Qin Kai, Lu Dahan, Qin Haibiao, Gu Jin, Chen Yongxi, Qin Haoran, Wei Jiading, Wu Liang, Song Quansheng. Lumbar spinal tuberculosis implanted with artificial bone with streptomycin sulfate and percutaneous pedicle screw under transforaminal endoscopy [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(4): 493-498. |
[10] | Li Li, Ma Li. Immobilization of lactase on magnetic chitosan microspheres and its effect on enzymatic properties [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(4): 576-581. |
[11] | He Jie, Chang Qi. Biological reconstruction of large bone defects after resection of malignant tumor of extremities [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(3): 420-425. |
[12] | Yu Langbo, Qing Mingsong, Zhao Chuntao, Peng Jiachen. Hot issues in clinical application of dynamic contrast-enhanced magnetic resonance imaging in orthopedics [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(3): 449-455. |
[13] | Zhou Anqi, Tang Yufei, Wu Bingfeng, Xiang Lin. Designing of periosteum tissue engineering: combination of generality and individuality [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(22): 3551-3557. |
[14] | Huo Hua, Cheng Yuting, Zhou Qian, Qi Yuhan, Wu Chao, Shi Qianhui, Yang Tongjing, Liao Jian, Hong Wei. Effects of drug coating on implant surface on the osseointegration [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(22): 3558-3564. |
[15] | Lang Limin, He Sheng, Jiang Zengyu, Hu Yiyi, Zhang Zhixing, Liang Minqian. Application progress of conductive composite materials in the field of tissue engineering treatment of myocardial infarction [J]. Chinese Journal of Tissue Engineering Research, 2021, 25(22): 3584-3590. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||